308 results about "Nephropathy" patented technology

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The embodiment of the invention discloses a model optimization method based on transfer learning. The method comprises the following steps: acquiring to-be-migrated learning data, wherein the to-be-migrated learning data comprises source domain data associated with pathological characteristics of kidney diseases; semantic alignment processing is carried out on the source domain data and target domain data, the target domain data is kidney disease pathology data, and a semantic alignment result is obtained; determining a feature distribution result corresponding to the target domain data, and determining a migration weight corresponding to the source domain data based on the feature distribution result and the semantic alignment result; and optimizing the target domain model based on the migration weight, the source domain data and the target domain data to obtain an optimized target domain model. According to the embodiment of the invention, the accuracy and robustness of the target domain model in a kidney disease pathological diagnosis task and the generalization ability of different data distributions can be remarkably improved.

The present application relates to heterobicyclic compounds having glucagon-like peptide receptor (GLP-1R) agonist activity, processes for their preparation, pharmaceutical compositions comprising them and their use as GLP-1R agonists or for the treatment or prophylaxis of GLP-1R associated diseases or disorders. In particular, the compounds of the present application are useful for body weight management, for lowering blood sugar and / or for the treatment or prevention of diabetes, diabetic complications, obesity, overweight, dyslipidemia, fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)), metabolic diseases, cardiovascular diseases, nervous system disorders, mental disorders, kidney diseases, etc. , gastrointestinal diseases, autoimmune diseases, inflammatory diseases, lung diseases, hypothalamic-pituitary-gonad axis related diseases or disorders, cancers and the like.

The invention provides a construction method and system of a heart failure risk prediction model based on medical big data and a machine learning algorithm, and a medium, and the construction method comprises the steps: screening a medical information database, and obtaining a kidney patient group information data set; preprocessing the data set, dividing a training set, a verification set and a plurality of candidate prediction factors related to the heart failure risk, performing importance sorting, and training through a machine learning algorithm according to an importance sorting result and the training set to obtain a plurality of candidate heart failure risk prediction models; and evaluating and comparing the candidate models according to the verification set, and finally obtaining a heart failure risk prediction model. The heart failure risk prediction model specially designed for the chronic kidney patient group is constructed based on the medical big data and the machine learning algorithm, the heart failure risk prediction accuracy for the kidney patient group can be effectively improved, and the method can be widely applied to the technical field of medical information prediction.

The invention relates to the technical field of medical care informatics, in particular to a nephropathy medication interaction risk screening system which comprises a data acquisition unit, an SOC chip processing and analysis unit, a risk early warning unit and a man-machine interaction and communication unit. Through multi-source data access, dynamic weight scheduling and Kalman filtering fusion correction, accurate and on-demand acquisition of nephropathy core indexes is realized, and real-time intelligent discrimination of personalized medication risks is realized by relying on knowledge base support, adaptive path adjustment and a safe atomization updating mechanism, so that the risk of the nephropathy is accurately determined. Therefore, the problems that traditional system data acquisition lacks specialized pertinence, risk assessment personalization is insufficient, and model updating is lagged are effectively solved, and the accuracy and timeliness of nephropathy medication interaction risk screening are remarkably improved.

The invention provides application of a product of targeted Vasorin protein in preparation of a product for diagnosing or treating kidney diseases with reduced glucose tolerance, and belongs to the technical field of biological medicines. Vasorin is used as a biomarker of the hypoglucose tolerance nephropathy, the level of Vasorin in urine of a patient is absolutely quantified through an ELISA technology, and the Vasorin has great clinical value and practical significance in early discovery and intervention of the hypoglucose tolerance nephropathy. According to the present invention, the gene or the Vasorin protein for controlling the Vasorin expression is adopted as the target spot, and the specific vector is adopted to perform overexpression on the Vasorin protein, such that the lipid droplet deposition and the reactive oxygen species (ROS) overgeneration in the renal tubular epithelial cell can be effectively improved, and the albumin reabsorption ability of the renal tubular can be improved so as to effectively treat the glucose tolerance reduced nephropathy.

Certain aspects of the present disclosure provide a monitoring system comprising a continuous analyte sensor configured to penetrate a skin of a patient and generate a sensor current indicative of analyte levels of the patient, and a sensor electronics module coupled to the continuous analyte sensor. The sensor electronics module comprises an analog to digital converter configured to receive the sensor current and convert the sensor current generated by the continuous analyte sensor into digital signals, a processor configured to convert the digital signals to a set of analyte measurements indicative of the analyte levels of the patient, and a Bluetooth antenna configured to transmit the set of analyte measurements wirelessly to a wireless communications device using Bluetooth or BLE communications protocols.

According to various aspects of this disclosure, the present disclosure relates to methods for reducing kidney inflammation, reducing kidney fibrosis, reducing oxidative stress in the kidney, preventing or reducing the likelihood of chronic kidney disease (CKD), treating or preventing acute kidney injury (AKI) or treating a kidney disease in a subject in need thereof comprising administering, e.g., intramuscularly, to the subject a recombinant adeno-associated virus (rAAV) vector, wherein the rAAV vector comprises a vector genome comprising a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) or a functional fragment thereof and an AAV capsid (e.g., AAV1 serotype), optionally, wherein the subject does not suffer from diabetes.

The invention relates to the technical field of image recognition, and discloses an image feature recognition method and system applied to the early stage of kidney diseases. According to the method, the features in the original ultrasonic image are extracted in parallel, and the micro texture change and the macroscopic form information shown in the abnormal area can be captured respectively, so that the limitation of a traditional single-scale feature extraction method in coping with diffusive and weak-saliency image features is overcome; the local texture feature map and the global structure feature map are analyzed, quantization and positioning of weak texture changes are achieved, priori knowledge is converted into objective indexes, pixel-level fusion is carried out on a texture abnormal map and a region importance weight map, and through the knowledge-guided and data-driven deep fusion method, the deep fusion of the texture abnormal map and the region importance weight map is achieved. It is ensured that the finally recognized abnormal area is not only a statistical outlier but also conforms to importance distribution of an image structure, and high-precision automatic recognition of weak and diffuse features in the kidney medical image is facilitated.

Provided are a method and a kit for quantifying L-FABP or oxidized L-FABP in any sample, a method and a kit for testing for kidney diseases on the basis of the quantifying result of L-FABP or oxidized L-FABP in urine of a subject, and a companion diagnostic drug. This method for quantifying liver type fatty acid binding protein includes a step for promoting an antigen-antibody reaction, and quantifying the liver type fatty acid binding protein under a condition in which the measurement sensitivity of oxidized liver type fatty acid binding protein is higher than that of unoxidized liver type fatty acid binding protein.

The invention relates to proteins for use in the prevention, treatment or amelioration of kidney diseases or kidney damage, more particularly where the protein is a follistatin-fusion protein.

The present invention provides, in part, a novel small molecule PHD inhibitor having a structure according to Formula (A) or a sub-formula thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein are useful in the treatment of diseases, including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., acute lung injury, pulmonary arterial hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver diseases (e.g., acute liver failure and liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis). Acute kidney injury and chronic kidney disease).

The present disclosure provides a method and an apparatus for predicting a progression trajectory from acute kidney injury (AKI) to a kidney disease. The method includes the following steps: receiving a first set of features of a particular acute kidney injury (AKI) patient; selecting a second set of features from the first set of features using a preset algorithm; and predicting, using a first machine-learning model, a progression trajectory of a kidney disease of the particular AKI patient based on the second set of features.

To simply provide information showing a degree of a kidney disease of a feline animal.SOLUTION: A urine inspection system includes a storage part and a control part. The storage part stores kidney disease information on a relation between a level of a D-amino acid in urine of a feline animal and a degree of a kidney disease of the feline animal. The control part receives D-amino acid information showing the level of the D-amino acid in the urine from the feline animal from a user terminal belonging to an owner or an inspection institute of the feline animal. Then, the control part estimates the degree of the kidney disease of the feline animal on the basis of the received D-amino acid information and the kidney disease information and transmits kidney disease degree information showing the estimated degree of the kidney disease to the user terminal.SELECTED DRAWING: Figure 4

The invention relates to a construction method, an evaluation method and application of an inflammatory nephropathy animal model, and relates to the technical field of nephropathy animal model construction. The construction method comprises the steps that a CRIPSR / Cas9 system is adopted to shear a first targeting site on an Smu region of a mouse immune globulin gene, and a second targeting site on an Sgamma2c region of the mouse immune globulin gene is sheared, so that a base sequence between the first targeting site and the second targeting site is knocked out, and the inflammatory nephropathy animal model is obtained. The application comprises an application of the inflammatory nephropathy animal model constructed by the construction method in screening drugs for treating inflammatory nephropathy and an application in researching a molecular mechanism of occurrence and development of inflammatory nephropathy.

The invention discloses a method for constructing a pressed butterfly mycin glycoside gene engineering strain by using glycosyl transferase and application of the pressed butterfly mycin glycoside gene engineering strain. A strong promoter kasOp * is introduced to the upstream of a glucoside transferase gene pie28 of Streptomyces psammoticus SCSIO NS126, the nucleotide sequence of the strong promoter kasOp * is as shown in SEQ ID NO. 1, and the nucleotide sequence of the glucoside transferase pie28 is as shown in SEQ ID NO. 2. The invention also discloses a preparation method of the Streptomyces psammoticus SCSIO NS126, and the preparation method of the Streptomyces psammoticus SCSIO NS126 comprises the following steps of: introducing the strong promoter kasOp * into the upstream of the glucoside transferase gene pie28. The streptomyces gene engineering strain Streptomyces sp. SK-kas28 constructed by the invention can efficiently express the chalcone glycoside, is widely applied to fermentation production of the chalcone glycoside, and is used for research and development of new drugs for treating kidney diseases and the like.

In an illustrative embodiment, systems and methods for treating kidney disease in a human patient are disclosed. A method includes advancing a collapsible array of RF electrodes through a urinary tract of the patient in collapsed form and into a position in or near a renal pelvis. The effector is deployed to an expanded form to engage at least a portion of an interior wall of the renal pelvis. RF energy delivered through the array of electrodes target afferent nerves proximate the interior wall of the renal pelvis to inhibit or destroy their function. eGFR of the patient can be raised after treatment according to the method.

The invention relates to the technical field of health assessment, in particular to a remote monitoring method and system for kidney disease patients. Similarity is obtained according to trend items and season items of adjacent time sequence segments in the sign monitoring time sequence; obtaining a sign monitoring segment according to the similarity of all adjacent time sequence segments; clustering the physical sign monitoring sections of the patient, and obtaining an abnormal disturbance difference value according to the difference characteristics of the residual items corresponding to the physical sign monitoring sections in the physical sign state cluster; obtaining an abnormal characterization value according to the residual item corresponding to the physical sign monitoring section in the physical sign state cluster, the abnormal disturbance difference value and the physical sign monitoring section; and obtaining a comprehensive abnormal index according to the abnormal representation values of all the physical sign state clusters of the patient. According to the body difference characteristics of the patient and other patients in the patient cluster, the abnormal early warning index is obtained by integrating the difference characteristics of the abnormal indexes and the difference characteristics of the sign monitoring time sequence, and early warning is carried out, so that the accuracy of remotely monitoring the state of the patient is improved.

Use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof or an isotopically labeled compound thereof in the preparation of a drug for preventing or treating neurodegenerative diseases, autoimmune and systemic inflammatory diseases, metabolic and cardiovascular diseases, respiratory diseases, ophthalmic diseases, or kidney diseases.

Provided herein are compounds that are useful in treating cancer, metabolic disease, cardiovascular disease, and kidney disease.

This invention discloses the isolation, extraction, and novel application of a neutral, water-soluble polysaccharide from Sophora japonica extract. The invention extracts a water-soluble, neutral polysaccharide with a molecular weight between 20-22 kDa. This invention uses the Sophora japonica extract to treat renal interstitial fibrosis. Multiple studies, including cellular and animal studies, have demonstrated that the traditional Chinese medicine Sophora japonica can inhibit renal interstitial fibrosis, making it a potential drug for clinical application and bringing greater benefits to patients with kidney disease.

The present invention provides methods of using non-naturally occurring melanocortin analogs to increase body weight and / or increase food consumption in a subject having a kidney disease and / or a liver disease (e.g., chronic kidney disease, renal failure, non-alcoholic fatty liver disease (NAFLD)). Also provided are methods of stimulating appetite in a subject via administration of a non-naturally occurring melanocortin analogue. The non-naturally occurring melanocortin analogs may be present in pharmaceutical compositions and delivered via parenteral administration (e.g., subcutaneous injection). The methods improve appetite, increase food consumption, increase body weight, muscle mass, and / or fat mass in the subject.

The present application relates to the technical field of pharmaceutical analysis, and in particular to a combined analysis method for exploring the effect of Huangkui capsules on improving chronic kidney injury of tacrolimus based on metabolomics and proteomics. The combined analysis method of the present application explores how Huangkui capsules improve the mechanism of chronic kidney injury of tacrolimus from multiple dimensions, which is beneficial to in-depth analysis of the specific effects of Huangkui capsules at the molecular, cellular and tissue levels, reveals the key path and regulation mechanism of kidney protection, and can also provide a scientific basis for optimizing clinical application, further promoting the modernization of traditional Chinese medicine and its wide application in the treatment of kidney disease.

To provide a method for treating a proteinuric kidney disease.SOLUTION: There is provided a method comprising administering a predetermined daily dosage of effective amounts of voclosporin over a projected treatment period of at least 24 weeks. The method further comprises: (a) assessing an estimated Glomerular Filtration Rate (eGFR) of a subject at at least a first time point and a second time point on different days within the treatment period; and (b) (i) when the eGFR of the subject decreases by more than a target % to below a predetermined value between the first and second time points, reducing the daily dosage by units of 7.9 mg BID or discontinuing the administration of voclosporin to the subject; (ii) when the eGFR of the subject decreases by less than the target % between the first and second time points, continuing to administer the same predetermined daily dosage of voclosporin to the subject.SELECTED DRAWING: Figure 1

The invention relates to a specifically degraded KIM1 liposome, preparation thereof and application of the specifically degraded KIM1 liposome in preparation of medicines for treating kidney diseases, and belongs to the technical field of biological medicines. According to the invention, a KIM1 targeting polypeptide and an E3 ubiquitin ligase ligand (such as lenalidomide) are respectively modified on the surface of a liposome. The lipidosome capable of specifically degrading the KIM1 can be rapidly enriched in a damaged kidney after renal injury occurs, and the KIM1 protein level in the damaged kidney is degraded by 75%. Meanwhile, the druggability problems of poor solubility, low bioavailability and the like caused by large molecular weight of the compound in the PROTAC drug development process are avoided, and the technical problems that drugs are difficult to prepare and kidney injury drugs are lacked in the prior art are solved.

We provide TRPC5 inhibitors for use in treating or reducing the risk of developing kidney disease, diabetic retinopathy, anxiety disorders, depression, or cancer. [Solution] Compounds according to formula (I) or (II), and pharmaceutical compositions containing them are disclosed. A therapeutic method using a compound of formula (I) or (II) to treat, for example, kidney disease is also disclosed. JPEG2026086459000081.jpg3992

The utility model discloses an in vitro fixing device for a nephropathy dialysis tube, which comprises an adjusting semi-ring, an adjusting groove is arranged on the adjusting semi-ring, a moving groove is arranged at the side end of the adjusting semi-ring, the adjusting groove is communicated with the moving groove, a fixing piece is connected in the moving groove in a sliding way, a limiting piece is arranged on the fixing piece, and a locking piece is arranged at the side end of the moving groove; a user is allowed to accurately adjust the position of the fixing piece through the adjusting groove and the fixing piece in sliding connection, it is guaranteed that the dialysis tube is kept stable in the using process, the problem of dialysis tube displacement caused by position deviation or movement is solved, the safety and effectiveness of treatment can be improved, and the fixing piece can be fixed through the clamping block and the clamping plate in a matched mode. According to the fixing device for the dialysis tube, the dialysis tube can be effectively prevented from sliding or shifting in the fixing process, the triangular design of the clamping blocks is matched with the cross-shaped design of the clamping plates, it is ensured that the dialysis tube is firmly fixed, accidental movement, caused by external force or internal movement, of the dialysis tube is reduced, and therefore the comfort level of a patient and the stability of dialysis treatment are improved.